콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

View All Documentation

A-072

Supelco

Atenolol solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C14H22N2O3
CAS Number:
29122-68-7
Molecular Weight:
266.34
EC Number:
200-835-2
UNSPSC 코드:
41116107
NACRES:
NA.24

Grade

certified reference material

형태

liquid

특징

SNAP-N-SPIKE®, SNAP-N-SHOOT®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

농도

1.0 mg/mL in acetonitrile

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

clinical testing

형식

single component solution

저장 온도

2-8°C

SMILES string

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

InChI key

METKIMKYRPQLGS-UHFFFAOYSA-N

유전자 정보

human ... ADRB1(153)

관련 카테고리

일반 설명

Atenolol, commonly sold under the trade name Tenormin®, is a beta blocker used to treat a number of cardiac conditions from hypertension to angina. This Snap-N-Spike® Reference Solution is suitable for use in atenolol methods by LC/MS or GC/MS for applications such as clinical toxicology, forensic analysis, or pharmaceutical research.

법적 정보

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tenormin is a registered trademark of Astrazeneca UK

픽토그램

FlameExclamation mark
GHS02,GHS07

신호어

Danger

유해 및 위험 성명서

H225,H302 + H312 + H332,H319

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point (°F)

35.6 °F - closed cup

Flash Point (°C)

2 °C - closed cup

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Shinji Yamashita et al.
Pharmaceutical research, 30(4), 951-958 (2012-11-28)
To evaluate the time-profile of intragastric fluid volume in humans after intragastric administration of drug solution. Eight healthy volunteers were intragastrically administered 150 mL of drug solution containing atenolol (non-absorbable marker) and salicylic acid, then, aliquots of gastric fluid (ca. 2 mL)
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Michel Azizi et al.
Hypertension (Dallas, Tex. : 1979), 61(6), 1239-1245 (2013-04-24)
Dietary sodium, the main determinant of the pharmacodynamic response to renin-angiotensin system blockade, influences the pharmacokinetics of various cardiovascular drugs. We compared the effect of contrasted sodium diets on the pharmacokinetics of single oral doses of 8 mg candesartan cilexetil
H Sakurai et al.
Japanese circulation journal, 64(11), 893-896 (2000-12-08)
Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.